{"schema_version":"secwatch.filing_event.v1","accession":"0000926326-24-000030","form_type":"8-K","ticker":"OMCL","cik":"0000926326","company_name":"OMNICELL, INC.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.413708+00:00","generated_at":"2026-05-30T08:48:50.866942+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Omnicell Q3 revenue $282M (-5% YoY); raises FY2024 non-GAAP EBITDA & EPS guidance","bullets":["Q3 GAAP net income $9M ($0.19/diluted) vs. $6M ($0.12) YoY; non-GAAP EPS $0.56 vs. $0.62.","Total revenues $282M, down 5% YoY due to health system headwinds and XT Series cycle timing.","FY2024 guidance raised: non-GAAP EBITDA $129-134M, non-GAAP EPS $1.65-1.72.","Appointed Nnamdi Njoku as EVP & COO; cash $571M, $350M revolver undrawn.","Q4 2024 revenue guidance $295-305M; non-GAAP Q4 EPS $0.55-0.62."],"urls":{"canonical":"https://secwatch.observer/filing/0000926326-24-000030","json":"https://secwatch.observer/filing/0000926326-24-000030.json","markdown":"https://secwatch.observer/filing/0000926326-24-000030.md","text":"https://secwatch.observer/filing/0000926326-24-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926326/000092632624000030/0000926326-24-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926326/000092632624000030/omcl-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:48:50.866942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}